Related references
Note: Only part of the references are listed.Detecting single ORAI1 proteins within the plasma membrane reveals higher-order channel complexes
Dalia Alansary et al.
JOURNAL OF CELL SCIENCE (2020)
EGFR forms ligand-independent oligomers that are distinct from the active state
Patrick O. Byrne et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer
Aena Patel et al.
CANCERS (2020)
Anti-correlation of HER2 and focal adhesion complexes in the plasma membrane
Florian Weinberg et al.
PLOS ONE (2020)
Determining the Efficiency of Single Molecule Quantum Dot Labeling of HER2 in Breast Cancer Cells
Diana B. Peckys et al.
NANO LETTERS (2020)
Graphene Enclosure of Chemically Fixed Mammalian Cells for Liquid-Phase Electron Microscopy
Patricia Blach et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2020)
Neratinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2+metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.
Cristina Saura et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Amplified fluorescence imaging of HER2 dimerization on cancer cells by using a co-localization triggered DNA nanoassembly
Tiantian Yang et al.
MICROCHIMICA ACTA (2019)
Fix Your Membrane Receptor Imaging: Actin Cytoskeleton and CD4 Membrane Organization Disruption by Chemical Fixation
Pedro M. Pereira et al.
FRONTIERS IN IMMUNOLOGY (2019)
Visualisation of HER2 homodimers in single cells from HER2 overexpressing primary formalin fixed paraffin embedded tumour tissue
Diana B. Peckys et al.
MOLECULAR MEDICINE (2019)
Breast cancer
Nadia Harbeck et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Pyrotinib or Lapatinib Combined With Capecitabine in HER2?Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study
Fei Ma et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer
Sean P. Kennedy et al.
BREAST CANCER RESEARCH (2019)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
VIPER is a genetically encoded peptide tag for fluorescence and electron microscopy
Julia K. Doh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Direct visualization of single-molecule membrane protein interactions in living cells
Do-Hyeon Kim et al.
PLOS BIOLOGY (2018)
HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone
Kathleen C. Day et al.
CANCER RESEARCH (2017)
The scaffolding protein NHERF1 regulates the stability and activity of the tyrosine kinase HER2
Jaekwang Jeong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
Antonio Llombart-Cussac et al.
LANCET ONCOLOGY (2017)
Liquid-phase electron microscopy of molecular drug response in breast cancer cells reveals irresponsive cell subpopulations related to lack of HER2 homodimers
Diana B. Peckys et al.
MOLECULAR BIOLOGY OF THE CELL (2017)
Breast cancers with EGFR and HER2 co-amplification favor distant metastasis and poor clinical outcome
Peng Guo et al.
ONCOLOGY LETTERS (2017)
Cooperative but distinct early co-signaling events originate from ERBB2 and ERBB1 receptors upon trastuzumab treatment in breast cancer cells
Paola Bagnato et al.
ONCOTARGET (2017)
HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance
Babak Nami et al.
CANCERS (2017)
HER2 signaling regulates HER2 localization and membrane retention
Jaekwang Jeong et al.
PLOS ONE (2017)
Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
Shengnan Yu et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2017)
Graphene Liquid Enclosure for Single-Molecule Analysis of Membrane Proteins in Whole Cells Using Electron Microscopy
Indra N. Dahmke et al.
ACS NANO (2017)
Breast Cancer: Multiple Subtypes within a Tumor?
Syn Kok Yeo et al.
TRENDS IN CANCER (2017)
HER2 induced EMT and tumorigenicity in breast epithelial progenitor cells is inhibited by coexpression of EGFR
S. Ingthorsson et al.
ONCOGENE (2016)
Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells
Yingqiu Zhang et al.
CANCER LETTERS (2016)
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
Luca Gianni et al.
LANCET ONCOLOGY (2016)
High cell-surface density of HER2 deforms cell membranes
Inhee Chung et al.
NATURE COMMUNICATIONS (2016)
HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status
Gregory Weitsman et al.
ONCOTARGET (2016)
Critical importance of appropriate fixation conditions for faithful imaging of receptor microclusters
Tess A. Stanly et al.
BIOLOGY OPEN (2016)
Quantum dots for quantitative imaging: from single molecules to tissue
Tania Q. Vu et al.
CELL AND TISSUE RESEARCH (2015)
Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity
Helle J. Jacobsen et al.
CLINICAL CANCER RESEARCH (2015)
Image artifacts in Single Molecule Localization Microscopy: why optimization of sample preparation protocols matters
Donna R. Whelan et al.
SCIENTIFIC REPORTS (2015)
Studying the Stoichiometry of Epidermal Growth Factor Receptor in Intact Cells using Correlative Microscopy
Diana B. Peckys et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2015)
Local variations of HER2 dimerization in breast cancer cells discovered by correlative fluorescence and liquid electron microscopy
Diana B. Peckys et al.
SCIENCE ADVANCES (2015)
EGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression. On the possibility to target these receptors with radionuclides
Jorgen Carlsson et al.
RADIOLOGY AND ONCOLOGY (2015)
Breast cancer adaptive resistance: HER2 and cancer stem cell repopulation in a heterogeneous tumor society
Nadire Duru et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2014)
The EGFR Family: Not So Prototypical Receptor Tyrosine Kinases
Mark A. Lemmon et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2014)
The Mysterious Ways of ErbB2/HER2 Trafficking
Vibeke Bertelsen et al.
MEMBRANES (2014)
HER2 and Breast Cancer Stem Cells: More than Meets the Eye
Hasan Korkaya et al.
CANCER RESEARCH (2013)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
Multi-Color Single Particle Tracking with Quantum Dots
Eva C. Arnspang et al.
PLOS ONE (2012)
Gefitinib Induces Epidermal Growth Factor Receptor Dimers Which Alters the Interaction Characteristics with 125I-EGF
Hanna Bjorkelund et al.
PLOS ONE (2011)
Quantum Dots Brighten Biological Imaging
Richard J. Byers et al.
PROGRESS IN HISTOCHEMISTRY AND CYTOCHEMISTRY (2011)
EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance
Rajiv Dua et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Membrane molecules mobile even after chemical fixation
Kenji A. K. Tanaka et al.
NATURE METHODS (2010)
Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with Metastatic Capacity and a Distinct Molecular Signature
Emmanuelle Charafe-Jauffret et al.
CANCER RESEARCH (2009)
ErbB receptors and signaling pathways in cancer
Nancy E. Hynes et al.
CURRENT OPINION IN CELL BIOLOGY (2009)
A Novel Proximity Assay for the Detection of Proteins and Protein Complexes: Quantitation of HER1 and HER2 Total Protein Expression and Homodimerization in Formalin-fixed, Paraffin-Embedded Cell Lines and Breast Cancer Tissue
Yining Shi et al.
DIAGNOSTIC MOLECULAR PATHOLOGY (2009)
Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization
Juliana Bentes Hughes et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity
M. Scaltriti et al.
ONCOGENE (2009)
Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells
David L. Shattuck et al.
CANCER RESEARCH (2008)
The Application of Fluorescent Quantum Dots to Confocal, Multiphoton, and Electron Microscopic Imaging
Thomas J. Deerinck
TOXICOLOGIC PATHOLOGY (2008)
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Antoine E. Karnoub et al.
NATURE (2007)
EGFR associated expression profiles vary with breast tumor subtype
Katherine A. Hoadley et al.
BMC GENOMICS (2007)
Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry
Yun Xing et al.
NATURE PROTOCOLS (2007)
Correlated light and electron microscopic imaging of multiple endogenous proteins using Quantum dots
BNG Giepmans et al.
NATURE METHODS (2005)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
TO Nielsen et al.
CLINICAL CANCER RESEARCH (2004)
Glutaraldehyde: behavior in aqueous solution, reaction with proteins, and application to enzyme crosslinking
I Migneault et al.
BIOTECHNIQUES (2004)
Expression of the HERI-4 family of receptor tyrosine kinases in breast cancer
CJ Witton et al.
JOURNAL OF PATHOLOGY (2003)
Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2
P Nagy et al.
JOURNAL OF CELL SCIENCE (2002)
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)
YH Lu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Share Paper
